Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Price Reaction to Earnings Reports

View detailed tables showing price action before and after earnings announcements, ranging from intraday to one week out. Track how the market has reacted to past earnings to identify patterns and predict future behavior. Click here to open.

CYTO

Altamira Therapeutics Ltd

Dec 10 • 04:00PM ET

0.4598

Dollar change 0.0000
Percentage change 0.00	%

Healthcare • Biotechnology • Bermuda • NASD

Peers: JNJ PFE AMGN AZN LLY MRNA GILD BNTX NVAX INO

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	0.53%	Shs Outstand	3.78M	Perf Week	-3.97%
Market Cap	1.74M	Forward P/E	-	EPS next Y	-1.13	Insider Trans	0.00%	Shs Float	3.76M	Perf Month	-7.86%
Income	-	PEG	-	EPS next Q	-0.58	Inst Own	3.08%	Short Float	1.35%	Perf Quarter	-47.60%
Sales	-	P/S	-	EPS this Y	84.73%	Inst Trans	-	Short Ratio	0.42	Perf Half Y	-64.90%
Book/sh	2.37	P/B	0.19	EPS next Y	55.85%	ROA	-	Short Interest	0.05M	Perf Year	-94.39%
Cash/sh	0.02	P/C	24.86	EPS next 5Y	-	ROE	-	52W Range	0.40 - 7.38	Perf YTD	-86.79%
Dividend Est.	-	P/FCF	-	EPS past 5Y	50.52%	ROI	-	52W High	-93.77%	Beta	2.39
Dividend TTM	-	Quick Ratio	0.43	Sales past 5Y	-20.00%	Gross Margin	-	52W Low	14.95%	ATR (14)	0.06
Dividend Ex-Date	-	Current Ratio	0.43	EPS Y/Y TTM	5.52%	Oper. Margin	-	RSI (14)	46.80	Volatility	18.04% 15.17%
Employees	12	Debt/Eq	0.07	Sales Y/Y TTM	-	Profit Margin	-	Recom	1.00	Target Price	290.46
Option/Short	No / Yes	LT Debt/Eq	0.05	EPS Q/Q	87.98%	Payout	-	Rel Volume	0.00	Prev Close	0.46
Sales Surprise	-	EPS Surprise	10.45%	Sales Q/Q	-	Earnings	Sep 24 BMO	Avg Volume	119.62K	Price	0.46
SMA20	3.24%	SMA50	-10.80%	SMA200	-60.12%	Trades		Volume	0	Change	0.00%

Oct-04-24 04:01PM	Altamira Therapeutics Provides Update on Nasdaq Listing (GlobeNewswire) +8.08% -5.96%
Sep-27-24 09:01AM	Altamira Therapeutics Announces Extended ISO 13485 Quality Management System Certification for Bentrio Nasal Spray (GlobeNewswire)
Sep-24-24 08:01AM	Altamira Therapeutics Provides Business Update and First Half 2024 Financial Results (GlobeNewswire)
Sep-20-24 09:01AM	Altamira Therapeutics to Host First Half 2024 Financial Results and Business Update Call on September 24, 2024 (GlobeNewswire) -5.31%
Sep-19-24 04:01PM	Altamira Therapeutics Announces Closing of up to $12.0 Million Public Offering (GlobeNewswire)
05:00PM	Loading…
Sep-17-24 05:00PM	Altamira Therapeutics Announces Pricing of up to $12.0 Million Public Offering (GlobeNewswire)
Sep-16-24 08:30AM	Altamira Therapeutics Announces Expansion of Bentrio License and Distribution Agreement with Nuance Pharma in East and South East Asia (GlobeNewswire) -11.52%
Sep-03-24 09:01AM	Altamira Therapeutics to Present at H.C. Wainwright 26th Annual Global Investment Conference September 9-11 (GlobeNewswire)
Aug-26-24 10:41AM	REPEAT -- Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) (GlobeNewswire)
08:00AM	Diamond Equity Research Releases Update Note on Altamira Therapeutics Ltd. (NASDAQ: CYTO) (GlobeNewswire)
Aug-23-24 09:01AM	Altamira Therapeutics Announces Extension of Bentrio Distribution Agreement with Pharma Nordic to Include Sweden and Denmark (GlobeNewswire)
Aug-16-24 09:01AM	Altamira Therapeutics Announces Confirmed Suitability of Bentrio for Athletes as Comprehensive Testing Shows Absence of Prohibited Substances (GlobeNewswire) -5.21%
Aug-12-24 09:02AM	Altamira Therapeutics Announces Significant Enhancement of Immune Checkpoint Inhibition Therapy in Combination with Zbtb46 mRNA Delivered with SemaPhore Nanoparticles in Animal Tumor Models (GlobeNewswire) -6.36%
Jul-19-24 09:01AM	Altamira Therapeutics Announces Publication of Preclinical Data Showing Successful Treatment of Abdominal Aortic Aneurysm with SOD2 mRNA Delivered by SemaPhore Nanoparticles (GlobeNewswire) -10.45%
Jun-20-24 09:01AM	Altamira Therapeutics Highlights Newly Published Review Article Supporting Use of Betahistine in Vertigo Management (GlobeNewswire) -6.40%
10:31AM	Loading…
May-28-24 10:31AM	Altamira Therapeutics Provides Business Update (GlobeNewswire) -9.55%
May-24-24 08:45AM	Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to $7.4 Billion By 2032 (GlobeNewswire)
May-23-24 08:47AM	Altamira Therapeutics Announces Dissemination of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis Through Social Media Channels of Top Allergy Journal (GlobeNewswire) +19.58%
May-01-24 08:47AM	Altamira Therapeutics Announces Filing of Provisional Patent Application for OligoPhore Nanoparticles with siRNA Targeting p65 Protein in Treatment of Cancer and Inflammation (GlobeNewswire)
Apr-24-24 08:47AM	Altamira Therapeutics Announces Publication of Positive Results from Bentrio Trial in Seasonal Allergic Rhinitis in Top Peer Reviewed Journal (GlobeNewswire) -8.86%
Apr-17-24 08:00AM	Diamond Equity Research to Host Spotlight Emerging Growth Invitational Virtual Investor Conference on April 18, 2024 (GlobeNewswire) -9.20%
Apr-15-24 08:00AM	Diamond Equity Research Initiates Coverage on Altamira Therapeutics Ltd. (NASDAQ: CYTO) (GlobeNewswire) -9.29%
Apr-12-24 08:20AM	Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Apr-10-24 08:00AM	Altamira Therapeutics Provides Business Update, Reports Full Year 2023 Financial Results (GlobeNewswire) +7.53%
Apr-04-24 08:45AM	Altamira Therapeutics to Host Full Year 2023 Financial Results and Business Update Call on April 10, 2024 (GlobeNewswire) +7.73%
Mar-25-24 08:47AM	Altamira Therapeutics Announces Collaboration with Univercells Group on Nanoparticle-Delivered mRNA Vaccines (GlobeNewswire) +35.84%
Feb-07-24 08:47AM	Altamira Therapeutics' Peptide-Based Delivery Platform Shown to Enhance Potency of Commonly Used Gene Delivery Method as Published in Peer-Reviewed Journal (GlobeNewswire)
Jan-24-24 08:47AM	Altamira Therapeutics Files Second Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment (GlobeNewswire) +8.57%
Jan-08-24 08:47AM	Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit (GlobeNewswire)
Dec-29-23 08:47AM	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement (GlobeNewswire) +7.41%
05:51AM	Loading…
Dec-14-23 05:51AM	CYTO Stock Earnings: Altamira Therapeutics Reported Results for H1 2023 (InvestorPlace) -13.97%
Dec-11-23 08:00AM	Altamira Therapeutics Provides Investor and Business Update (GlobeNewswire) -53.79%
Dec-05-23 12:54PM	Altamira Therapeutics to Host Investor & Business Update Call on December 11th (GlobeNewswire) +18.92%
Nov-29-23 10:20AM	Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement (GlobeNewswire) +180.22%
Nov-27-23 08:48AM	Why Is Altamira Therapeutics (CYTO) Stock Down 8% Today? (InvestorPlace) -21.77%
Nov-17-23 02:45PM	Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today? (InvestorPlace) +180.28%
09:04AM	Altamira Therapeutics Announces Partial Spin-Off of Bentrio Business (GlobeNewswire)
Nov-10-23 08:47AM	Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine (GlobeNewswire) -11.25%
Sep-14-23 08:47AM	Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis (GlobeNewswire) -5.72%
Sep-12-23 07:30AM	Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results (GlobeNewswire) -6.03%
Sep-06-23 08:47AM	Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th (GlobeNewswire)
Aug-23-23 08:47AM	Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13 (GlobeNewswire)
Jul-20-23 08:47AM	Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia (GlobeNewswire)
Jul-17-23 08:47AM	Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal (GlobeNewswire)
Jul-06-23 08:00AM	Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering (ACCESSWIRE) -8.81%
Jul-05-23 08:47AM	Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration (GlobeNewswire) -6.70%
Jun-15-23 08:47AM	Altamira Therapeutics Announces IND Clearance by U.S. FDA for AM-125 in Acute Vestibular Syndrome (ACCESSWIRE)
May-31-23 04:30PM	Altamira Therapeutics Announces Publication of Peer-Reviewed Article on Peptide-Based RNA Delivery for Extrahepatic Targets (ACCESSWIRE)
May-24-23 08:47AM	Altamira Therapeutics Reports Positive Top-Line Data from Bentrio Clinical Trial in Seasonal Allergic Rhinitis (ACCESSWIRE)
May-16-23 07:30AM	Altamira Therapeutics Provides Business Update, Reports FY 2022 Financial Results (ACCESSWIRE)
May-12-23 08:47AM	Altamira Therapeutics to Host Fiscal Year 2022 Financial Results and Business Update Call on May 16th 2023 (ACCESSWIRE)
May-09-23 07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE) -7.89%
May-01-23 08:47AM	Altamira Therapeutics CEO & Chairman to Present at Sidoti Micro-Cap Virtual Conference May 10-11 (ACCESSWIRE) -11.93%
Apr-12-23 09:30AM	Altamira Therapeutics Announces Publication of Positive Results from Phase 2 Trial with AM-125 in Acute Vestibular Syndrome in Leading Peer Reviewed Journal (ACCESSWIRE) +59.09%
Apr-11-23 09:58AM	Altamira Therapeutics Positions its Patented SemaPhore mRNA Delivery Platform as Versatile and Efficient Alternative to Lipid Nanoparticles (ACCESSWIRE) -36.23%
Apr-10-23 08:47AM	Altamira Therapeutics Reports Positive Conclusions from Independent Meta-Analysis of Clinical Studies with Betahistine in Treatment of Most Common Cause of Vertigo (ACCESSWIRE) +12.50%
Mar-22-23 08:47AM	Altamira Therapeutics SemaPhore Delivery Platform Shows Significant Synergis-tic Effects of ZBTB46 mRNA with PD1 Immunotherapy in Control of Tumor Growth in Animal Model (GlobeNewswire)
Mar-15-23 08:47AM	Altamira Therapeutics SemaPhore RNA Delivery Platform Drives Effective Treatment of Osteoarthritis with mRNA in Animal Model (ACCESSWIRE)
Mar-03-23 08:47AM	Clinical Study Demonstrates Bentrio's Superior Nasal Residence Time and Rheological Properties (ACCESSWIRE) +5.51%
Feb-27-23 08:47AM	Altamira Therapeutics Files Provisional Patent Application for OligoPhore Nanoparticles Targeting Different KRAS Mutations in Cancer Treatment (GlobeNewswire)
Feb-14-23 08:47AM	Altamira Therapeutics to Report Bentrio Clinical Data, in House Dust Mite and Grass Pollen Allergic Rhinitis, at Feb. 25 AAAAI Annual Meeting (ACCESSWIRE)
Feb-07-23 08:47AM	Altamira Therapeutics to Present at Two Upcoming RNA Therapeutics Conferences in Q1 2023 (ACCESSWIRE)
Jan-27-23 08:47AM	Altamira Therapeutics Provides Business Update (GlobeNewswire) -12.89%
Jan-24-23 08:17AM	Altamira Therapeutics Provides Update on Clinical Trials with Bentrio (GlobeNewswire) -29.12%
Jan-10-23 08:47AM	Altamira Therapeutics to Present at 2nd Annual mRNA-Based Therapeutics Summit Europe Conference January 24th to 26th (GlobeNewswire)
Dec-19-22 08:47AM	Altamira Therapeutics Provides Year-End 2022 Business Update (GlobeNewswire) -14.16%
Dec-02-22 08:47AM	Altamira Therapeutics Reaches Midpoint for Enrollment in Clinical Trial with Bentrio in Seasonal Allergic Rhinitis in Australia (ACCESSWIRE)
Nov-30-22 08:47AM	Altamira Therapeutics Provides Business Update and First Half 2022 Financial Results (GlobeNewswire) -6.77%
08:07AM	Altamira Therapeutics Announces Launch of Bentrio in Hong Kong by its Partner Nuance Pharma (GlobeNewswire)
Nov-22-22 08:47AM	In Vivo Data Presented at AHA Conference Demonstrates Altamira Therapeutics' SemaPhore mRNA Delivery Platform to Effectively Help Preserve Atherosclerotic Plaque Stability (ACCESSWIRE) +6.27%
Nov-10-22 08:47AM	Altamira Therapeutics to Participate at TIDES Europe Oligonucleotide and Peptide Therapeutics Hybrid Event (GlobeNewswire)
Nov-09-22 08:47AM	Altamira Therapeutics Regains Listing Compliance with NASDAQ Minimum Bid Requirement (GlobeNewswire) -9.52%
Nov-08-22 08:47AM	Data Published in Peer-Reviewed Journal Demonstrate Protective Effects of Altamiras Bentrio under Controlled Grass Pollen Exposure (GlobeNewswire)
Oct-24-22 08:47AM	Altamira Therapeutics Announces Reverse Stock Split (GlobeNewswire) -24.96%
Oct-21-22 08:47AM	Altamira Therapeutics Announces Divestiture of Inner Ear Development Assets (GlobeNewswire) +58.64%
Oct-13-22 08:47AM	Altamira Therapeutics to Participate at RNA Leaders USA Congress (GlobeNewswire)
Oct-03-22 08:47AM	Altamira Therapeutics Continue Bentrio Clinical Trial for Seasonal Allergic Rhinitis in Australia (GlobeNewswire) -7.42%
Sep-27-22 08:47AM	Altamira Therapeutics Re-launches Bentrio in Europe for Allergic Rhinitis (GlobeNewswire) +7.72%
Sep-13-22 08:47AM	Altamira Therapeutics Completes Enrollment for COVAMID Trial with Bentrio in Acute COVID-19 (GlobeNewswire)
Sep-08-22 08:57AM	Altamira Therapeutics to Host Investor Call on September 14th (GlobeNewswire) -9.31%
07:17AM	Altamira Therapeutics to Participate in the 4th Annual RAS-Targeted Drug Development Summit (GlobeNewswire)
Aug-30-22 09:24AM	Altamira Therapeutics Provides Business Update (GlobeNewswire) -5.94%
Aug-03-22 12:15PM	Altamira Therapeutics CEO Interviewed by Proactive Investors to Discuss its Pipeline of RNA Therapeutics and Ongoing Strategic Transformation (GlobeNewswire)
Aug-01-22 08:47AM	Altamira Therapeutics Completes Interim Sample Size Analysis of COVAMID Trial with Bentrio in Acute COVID-19 (GlobeNewswire) -5.55%
Jul-28-22 08:47AM	Altamira Therapeutics Delivery Platform with siRNA Shown to be Effective Treatment for Osteoarthritis as Published in Peer-Reviewed Journal (GlobeNewswire) +7.14%
Jul-25-22 08:47AM	Altamira Therapeutics to Develop Novel Generation of Rheumatoid Arthritis Therapeutics Based on its Proprietary OligoPhore Delivery Platform and siRNA Targeting Key Inflammation Checkpoint (GlobeNewswire)
Jul-19-22 08:47AM	Altamira Therapeutic's SemaPhore Platform Shown Particularly Effective in Intracellular mRNA Delivery for Cancer Therapy (GlobeNewswire) +17.11%
Jul-12-22 08:47AM	Altamira Therapeutics RNA Delivery Platform Shown to be an Effective Treatment for Abdominal Aortic Aneurysm as Published in Peer-Reviewed Journal (ACCESSWIRE) +11.32%
Jun-29-22 07:30AM	Altamira Therapeutics Secures Marketing & Distribution Agreements To Expand Sales Channels of Bentrio into Egypt and Pakistan (ACCESSWIRE)
Jun-27-22 08:30AM	Altamira Therapeutics Receives FDA 510(k) Clearance for Bentrio to Treat Allergic Rhinitis (ACCESSWIRE) +11.57%
Jun-23-22 08:47AM	Altamira Therapeutics Achieves COVAMID Trial Target Enrollment for Bentrio in Acute COVID-19 (ACCESSWIRE)
Jun-13-22 08:47AM	Altamira Therapeutics Announces Top-Line Data from AM-125 Phase 2 Study in Acute Vertigo (ACCESSWIRE) -5.85%
Jun-09-22 05:25PM	Altamira Therapeutics Receives NASDAQ Notification Regarding Minimum Bid Requirements (ACCESSWIRE) -10.24%
Jun-08-22 08:47AM	Altamira Therapeutics Reports 89.5% and 98.9% Reduction in Viral Load Against Human Rhinovirus With its Bentrio Nasal Spray (ACCESSWIRE)
May-31-22 08:47AM	Altamira Therapeutics Announces Marketing Approval for Bentrio Nasal Spray in Indonesia (ACCESSWIRE)
May-23-22 08:47AM	Altamira Therapeutics Receives Philippines' FDA Approval of Bentrio Nasal Spray (ACCESSWIRE)
May-20-22 09:00AM	Altamira Therapeutics Announces Positive Top-line Results from its Clinical Trial with Bentrio Nasal Spray in House Dust Mite Study (ACCESSWIRE)
May-19-22 09:00AM	Altamira Therapeutics to Present at the 2022 H.C. Wainwright Global Investment Conference (ACCESSWIRE) +5.68%
May-18-22 08:47AM	Altamira Therapeutics Issues Shareholder Letter (ACCESSWIRE)
May-05-22 08:47AM	Altamira Receives Regulatory Approval from the Ministry of Health to Expand COVAMID Trial for Bentrio in Acute COVID-19 into North Macedonia (ACCESSWIRE)

Altamira Therapeutics Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through the Switzerland and Australia geographical segments. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CYTO

Altamira Therapeutics Ltd

Upgrade your FINVIZ experience